Axsome Therapeutics Inc
Closed
SectorHealthcare
144.04 -6.97
Overview
Share price change
24h
Min
143.3
Max
154.83
Income | 13M -51M |
|---|---|
Sales | 27M 218M |
EPS | -0.99 |
Profit margin | -23.498 |
Employees | 1,346 |
EBITDA | 14M -47M |
Recommendations | Strong Buy |
|---|---|
12 Months Forecast | +82.89% upside |
Next Earnings | 2 Nov 2026 |
|---|
Market Cap | -2.7B 8.2B |
|---|---|
Previous open | 151.01 |
Previous close | 144.04 |
Axsome Therapeutics Inc Chart
Past performance is not a reliable indicator of future results.
Related News
Peer Comparison
Price change
Axsome Therapeutics Inc Forecast
Price Target
By TipRanks
82.89% upside
12 Months Forecast
Average 285.875 USD 82.89%
High 380 USD
Low 247 USD
Based on 17 Wall Street analysts offering 12 month price targets forAxsome Therapeutics Inc - Dist in the last 3 months.
Financials
Selling and administration expenses
Operating expenses
Pre-tax profit
Sales
Cost of sales
Gross profit on sales
Interest expense on debt
EBITDA
Operating profit
$
About Axsome Therapeutics Inc
Axsome Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea. It is also developing AXS-05, which is in Phase III clinical trial to treat Alzheimer's disease agitation, as well as that has completed phase II clinical trial for the treatment of smoking cessation; AXS-07, an investigational medicine that has completed Phase III trials for the acute treatment of migraine; AXS-12, an investigational medicine, which is in Phase III trial to treat narcolepsy; AXS-14, a selective and potent norepinephrine reuptake inhibitor that has completed Phase III trial for the treatment of fibromyalgia and other conditions; and solriamfetol, a dual-acting dopamine and norepinephrine reuptake inhibitor, which has completed a Phase 2 trial for treating attention-deficit/hyperactivity disorder, and is in phase 2 major depressive, binge eating, and shift work disorder. Axsome Therapeutics, Inc. has a research collaboration agreement with Duke University for evaluating AXS-05 in smoking cessation. The company was incorporated in 2012 and is based in New York, New York.